Sun Pharma gets DCGI nod to launch generic semaglutide for weight management

Sun Pharma has gained the green light from the DCGI for its much-anticipated generic version of semaglutide injection, targeting chronic weight management under the name Noveltreat. With Novo Nordisk's patent expiration on the horizon, this initiative marks a pivotal moment in accessible healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9YVxW2L
via IFTTT

Read More

Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expiry

Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GLP-1 receptor agonist will be available after patent expiry, offering a crucial treatment option for India's growing obesity and diabetes burden. The approval follows successful Indian clinical trials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ijY5MyZ
via IFTTT

Read More

New drugs could reach market sooner as govt halves trial review timeline

The Indian government is shaking up the pharmaceutical sector by slashing the review period for manufacturing applications for new drugs to 45 days. Now, manufacturers can initiate clinical trials or bioequivalence studies with just a prior notification to the regulators, ditching the old requirement for express permission.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Np3P9nl
via IFTTT

Read More

Bastar's first super-specialty hospital opens

Bastar region will soon have its first super specialty hospital. Located in Jagdalpur, the facility opens in February. Hyderabad-based Continental Hospitals partners with the Chhattisgarh government. This 240-bedded hospital will offer advanced medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4FoeWz6
via IFTTT

Read More

Budget 2026: Industry leaders seek funding framework for innovation, R&D in pharma, MedTech

Industry leaders are calling for a structured funding framework in the upcoming Union Budget. This aims to boost innovation and R&D in India's pharmaceutical and MedTech sectors. The goal is to drive advanced research and achieve the Viksit Bharat vision. Companies seek support for complex therapies and improved patient access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GsVdtYK
via IFTTT

Read More

Zydus launches biosimilar for treatment of multiple cancers

Zydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha will be available in 100 mg and 40 mg dosages. The prices are significantly lower than the reference drug. This launch expands access to immuno-oncology therapies. The company aims to support patients with consistent care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mgIh9iF
via IFTTT

Read More

Over 160 drug samples found sub-standard in December

A recent inspection by India's drug regulator has revealed a troubling statistic: 167 medication samples were classified as not of standard quality (NSQ) in December, with valuable insights from both central and state laboratories aiding the findings. Many of these samples consisted of widely used drugs, highlighting a critical need for heightened quality control.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5euzjas
via IFTTT

Read More